Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Senti Biosciences, Inc.

CIK 1854270 SNTI·Biological Products · All EDGAR filings ↗

Material weakness Filing comparison

Senti Biosciences, Inc. reported internal control effective again after a material weakness

Material weakness in internal control Internal control reported effective

The weakness was first reported on 2025-03-20 — 372 days and 1 annual report before this one.

Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded our internal control over financial reporting was effective as of December 31, 2025. Item 9B. Other Information (a) Termination of Amended and Restated ChEF Purchase Agreement On March 17, 2025, Chardan acknowledged and accepted our written notice to terminate the A&R Purchase Agreement, waived its right to prior written notice and mutually agreed to terminate the A&R Purchase Agreement, effective…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-20
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
Yes
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
1
Weakness days reported
372
Weakness first reported
2025-03-20
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.